A urological catheter that features a camera and a light to guide implantation is planning the second-generation version of its medical device. However, it’ll likely be a year or two before Columbus, Ohio-based PercuVision rolls out version 2.0 of its DirectVision System, which is designed to address urinary catheter problems and improve the Foley catheter […]
Urinary incontinence products maker Uroplasty (NASDAQ:UPI) announced Monday that two private payers have agreed to cover its overactive bladder treatment. The Minnetonka, Minnesota-based urology firm has been winning coverage for its Urgent PC Neuromodulation treatment, which began with getting reimbursement from Medicare in November. And Wall Street has noticed. In the past year, the stock […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The specialty medical equipment company Future Path Medical has received regulatory clearance for its first product: a urine bag monitored with wireless technology. The Columbus, Ohio-area company received 510(k) clearance from the U.S. Food and Drug Administration for its iBag System, an FDA spokeswoman said. Future Path’s urine bag system could help prevent deaths from […]
Private insurers and Medicare regional carriers who decided to cover Uroplasty’s primary urinary incontinence product and other positive developments buoyed Uroplasty Inc.’s fiscal fourth-quarter sales numbers. The Minnetonka, Minnesota company announced that in the quarter ended March 31, sales jumped 35 percent to $4.01 million from $2.98 million in the same quarter a year ago. […]
Urological catheterization company PercuVision has been awarded a $1.4 million commercialization loan by the Ohio Department of Development (ODOD). The loan will go toward a $1.9 million project in which the Westerville, Ohio-based company will create "customer demonstration units" for hospitals, Chief Operating Officer Earl Singh said.
Uroplasty‘s performance finally “began to reflect the potential of the company” in the third quarter, CEO David Kaysen said Thursday during the company’s earnings call. The Minnetonka, Minnesota, device company ramped up its sales force, won over five new regional Medicare carriers, and boosted global sales by 14 percent to $3.5 million during the quarter, […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Plymouth-based company develops devices for treating enlarged prostate, or benign prostatic hyperplasia. Its Targis System uses microwave energy to heat and destroy enlarged prostate tissue as an alternative to pharmaceutical treatment. "The second quarter's results are disappointing and inconsistent with the efforts towards sustained, sequential revenue growth," CEO Stryker Warren Jr. said during the company's conference call.
GT Urological has raised $4.56 million from the sale of equity, according to documents filed with the Securities and Exchange Commission.
Uroplasty Inc. (NASDAQ:UPI) suffered a setback for insurance coverage of its Urgent PC Neuromodulation system. After Jan. 3, use of the posterior tibial nerve stimulation device will no longer be paid for by National Government Services, a regional Medicare carrier that operates in Connecticut, Indiana, Kentucky and New York, the company revealed today. The loss […]
An additional regional Medicare carrier is now covering overactive bladder treatment using Uroplasty Inc. (NASDAQ:UPI) Urgent PC Neuromodulation System. Palmetto GBA for California, Nevada and Hawaii now covers posterior tibial nerve stimulation using the device, according to the company. Lawrence, Kansas-based Palmetto GBA LLC is a contracted company that pays claims for Medicare professional services. The coverage approval […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Do you hear that? That's the sound of some mighty back-slapping at Uroplasty Inc.'s (NASDAQ:UPI) headquarters in Minnetonka, Minnesota. After winning Medicare reimbursement Wednesday for its urinary incontinence therapy, the company has seen its stock price jump more than 20 percent to around $5.35 per share.
Uroplasty Inc. lands reimbursement status from the Centers for Medicare and Medicaid Services for its posterior tibial nerve stimulation device for treating overactive bladder. Centers for Medicare and Medicaid Services awarded reimbursement status to Uroplasty Inc.’s (NSDQ:UPI) Urgent PC Neuromodulation System. When companies’ products are approved for coverage by the governmental agency, private-pay insurance companies […]
Akron General Health System is acquiring a cancer treatment center from the region’s largest urology practice. The health system announced on Wednesday that it is buying Physicians Urology’s outpatient prostate cancer treatment center on West Exchange Street near the hospital campus, effective Aug. 1. Under the deal, Akron General will contract with the 12-physician practice […]
Suppose you’re a woman suffering from urinary incontinence, a rather unpleasant feeling. A surgeon implants a balloon device, allowing you to pee or to pee less. But the company who makes the device now wants to turn off the device for a week or two and then reactive it to prove to the Food and […]
If the Food and Drug Administration has been too cozy with medical device companies in recent years, as some critics charge, Uromedica Inc. must have missed the memo. Since 2000, the Plymouth, Minn.-based company has been haggling with the FDA over its balloon device to treat urinary incontinence. Ten years and several clinical studies later, […]